Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocos
- Development stage
- Unknown
- Lead developer
- Percos
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ocos is a veterinary nutritional supplement developed by Percos and marketed under its affiliate Aranex. Formulated as an oral tablet for dogs and other pets, it is designed to support skeletal system growth, maintain strong bones and teeth, and promote joint health. The supplement contains an optimal ratio of calcium to phosphorus, enriched with microcrystalline hydroxyapatite complex (MCHC) as a source of elemental calcium, elemental phosphorus, and vitamin A. It is particularly indicated to meet the increased nutritional demands of pets during growth, pregnancy, and lactation.
- Brand names
- OcosOcos Calcium Supplement Tablet
- Other names
- Aranex Ocos Calcium Supplement Tablet
Beyond the preview
Go deeper on Ocos.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocos.